Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UQCRB | P14927 | 2/20 | 0.71 |
| ▸ | CA12 | O43570 | 2/20 | 0.69 |
| ▸ | CA9 | Q16790 | 2/20 | 0.69 |
| ▸ | CA1 | P00915 | 1/20 | 0.69 |
| ▸ | CA2 | P00918 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 5/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | POLB | P06746 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.67 |
| ▸ | FGB | P02675 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.67 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.67 |
| ▸ | PLEC | Q15149 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL893905 | 0.90 | CA12 (0.73) | CA12CA9CA1CA2MEN1 | |
| SCHEMBL3715141 | 0.90 | CA12 (0.75) | CA12CA9CA1CA2MEN1 | |
| SCHEMBL13028459 | 0.88 | GFER (0.77) | CA12CA9CA1CA2MEN1 | |
| SCHEMBL13028457 | 0.88 | WDR5 (0.68) | UQCRBCA12CA9CA1CA2 | |
| SCHEMBL5047573 | 0.86 | MEN1 (0.70) | UQCRBCA12CA9MEN1KMT2A | |
| SCHEMBL10093054 | 0.85 | GPR55 (0.69) | UQCRBCA12CA9MEN1KMT2A | |
| SCHEMBL13480185 | 0.84 | KMT2A (0.77) | UQCRBCA12CA9CA1CA2 | |
| SCHEMBL812677 | 0.84 | KMT2A (0.77) | UQCRBCA12CA9CA1CA2 | |
| SCHEMBL13028454 | 0.84 | GFER (0.67) | CA12CA9CA1CA2POLB | |
| SCHEMBL6296969 | 0.83 | UQCRB (1.00) | UQCRBCA12CA9CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240325340-A1 | ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE | LANDAUER, STEPHEN PAUL | 2024-10-03 | — | — | US | claimed |
| WO-2023009629-A1 | ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE | THOMAS JEFFERSON UNIVERSITY (US) | 2023-02-02 | — | — | WO | claimed |
| US-20240325340-A1 | ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE | LANDAUER, STEPHEN PAUL | 2024-10-03 | — | — | US | disclosed |
| WO-2023009629-A1 | ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE | THOMAS JEFFERSON UNIVERSITY (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20080146623-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | METHYLGENE INC. (CA) | 2008-06-19 | — | — | US | disclosed |
| US-RE39850-E1 | Aryl amide, -sulfonamide, or -urea derivatives; antiproliferative, antitumor, anticarcinogenic, and/or antimetastasis agents | METHYLGENE, INC. (CA) | 2007-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325340-A1 | ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE | AKT3, AKT1, AKT2 | UQCRB 4711/4885CA12 4842/4885CA9 4848/4885 |
| US-20080146623-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | HDAC1, HDAC3, HDAC11 | UQCRB 4744/4885CA12 1244/4885CA9 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.